By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Novan Therapeutics 

4222 Emperor Boulevard
Suite 200
Durham  North Carolina  27703  U.S.A.
Phone: 919-485-8080 Fax: n/a


SEARCH JOBS

Novan, Inc. is a late-stage specialty biotechnology company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide platform. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We are rapidly advancing programs in five dermatological conditions with significant unmet medical need. We believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market.

YEAR FOUNDED:

2008

LEADERSHIP:

CEO: Nathan Stasko

Chief Commercial Officer: Brian Johnson

CFO: Richard Peterson

Chief Medical Officer: M. Joyce Rico

CLINICAL TRIAL:

Please click here for clinical trial information.



Key Statistics


Email:
Ownership: Private

Web Site: Novan
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
Novan Files Paperwork for $60 Million IPO to Develop Skin Drugs 8/26/2016 6:33:24 AM
Novan Announces First Patient Dosed In Phase 2 Anti-Fungal Program 7/21/2016 7:24:14 AM
Novan Therapeutics Announces First Patient Dosed In Phase 3 Program For SB204 2/23/2016 7:37:07 AM
Novan Therapeutics Announces Robert A. Ingram As Chairman 2/8/2016 8:06:06 AM
Novan Therapeutics Receives $30 Million in New Financing, Remains Mum on Plans 12/22/2015 7:14:49 AM
Novan Therapeutics to Build New Manufacturing Site for its Experimental Acne Treatments 10/28/2015 6:51:25 AM
Novan Therapeutics Appoints Chief Financial Officer And Chief Commercial Officer To Leadership Team 10/7/2015 7:36:37 AM
Novan Therapeutics Announces Successful Phase IIb Clinical Trial Results With SB204 For The Treatment Of Acne Vulgaris 9/29/2015 5:56:15 AM
Novan Therapeutics Adds Clinical Exposure And Safety Data To SB204 Acne Program 6/10/2015 8:50:41 AM
Novan Therapeutics Secures $50 Million Private Financing; Funds Intended to Advance SB204 into Phase 3 3/30/2015 10:43:50 AM
123
//-->